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Abstract: Colistin is an effective antibiotic for treatment of most multidrug-resistant Gram-
negative bacteria. It is used currently as a last-line drug for infections due to severe Gram-
negative bacteria followed by an increase in resistance among Gram-negative bacteria.
Colistin resistance is considered a serious problem, due to a lack of alternative antibiotics.
Some bacteria, including Pseudomonas aeruginosa, Acinetobacter baumannii,
Enterobacteriaceae members, such as Escherichia coli, Salmonella spp., and Klebsiella
spp. have an acquired resistance against colistin. However, other bacteria, including
Serratia spp., Proteus spp. and Burkholderia spp. are naturally resistant to this antibiotic.
In addition, clinicians should be alert to the possibility of colistin resistance among multi-
drug-resistant bacteria and development through mutation or adaptation mechanisms.
Rapidly emerging bacterial resistance has made it harder for us to rely completely on the
discovery of new antibiotics; therefore, we need to have logical approaches to use old
antibiotics, such as colistin. This review presents current knowledge about the different
mechanisms of colistin resistance.
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Introduction
Antibiotic resistance, which started in the 1970s among Gram-negative bacteria, is
a crucial global problem.1–3 Development of antibiotic resistance is a phenomenon
correlated with antibiotic overuse and bacterial evolution.4 Microorganisms can use
several mechanisms to adapt against antimicrobial agents and environmental sti-
mulants. Bacteria can use genetic alterations in their genes to form genes with
improved performance to overcome antibiotics. Modification in only a few base
pairs in DNA causing replacement of one or a few amino acids in an important
target, such as cell structure or cell wall and enzymes, leads to new resistance
strains.5 Initially, the problem of bacterial resistance to antibiotics was solved by the
invention of the latest categories of antibiotics, including aminoglycosides, glico-
peptides, and macrolides, and further by the c
hemical modification of old antibiotics. Unfortunately, these antibiotics could
not keep pace with the development of antibiotic resistance in bacterial
pathogens.6 Mobile genes conferring resistance to aminoglycosides and broad-
spectrum β-lactams can transfer between species and are one of the important
factors accounting for the progressive erosion of antimicrobial activity in both
hospital and community settings.7 Emergence of multidrug-resistant (MDR) and
extensively drug-resistant (XDR) Gram-negative bacteria, as well as the lack of
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novel agents against these pathogens, have led to the
reintroduction of colistin, an old and valuable antibiotic
as a last-resort treatment option.8
Colistin, also known as polymyxin E, was isolated in
1947 from the bacterium Paenibacillus polymyxa subsp.
colistinus.9 This organism also produces colistinase, which
inactivates colistin.10 Colistin is a polycationic antibiotic, and
has significant activity against Gram negative bacteria, such
as Enterobacteriaceae. The outer cell membrane of Gram-
negative bacteria is the main site of action for colistin.
When colistin binds to lipopolysaccharides in the
outer membrane, electrostatic interaction occurr between the
α,γ-diaminobutyric acid of colistin and the phosphate groups
of the lipid A region of lipopolysaccharide (LPS). It compe-
titively displaces divalent cations (Ca2+ and Mg2+) from the
phosphate groups of membrane lipids.11,12 Therefore, disrup-
tion of LPS may cause increased permeability of the outer
membrane and leakage of intracellular contents, ultimately
leading to cell death.13–15 Unfortunately, during the last few
decades, the emergence of colistin-resistant isolates has been
frequently reported,10,12 which has increased inappropriate
use of this drug, especially as monotherapy could be the
cause of this problem.16–18 In addition, there have been
reports of increased infection due to bacteria with intrinsic
resistance to colistin, such as Proteus spp., Providencia spp.,
Serratia spp., and Morganella spp.19–21 In this article, we
assess different mechanisms of colistin resistance in
Enterobacteriaceae.
Activity spectrum of colistin
Colistin is a narrow-spectrum antimicrobial agent that has
significant activity against most members of the
Enterobacteriaceae family, including Escherichia coli,
Enterobacter spp., Klebsiella spp., Citrobacter spp.,
Salmonella spp., and Shigella spp. It also has activity
against common nonfermentative Gram-negative bacteria,
such as Acinetobacter baumannii, Pseudomonas aerugi-
nosa, and Stenotrophomonas maltophilia.14,22–24 In addi-
tion, Haemophilus influenzae, Legionella pneumophila,
Aeromonas spp., and Bordetella pertussis are naturally
susceptible to colistin.15,22,25,26
Conversely, among the Enterobacteriaceae, Proteus
spp. and Serratia marcescens have intrinsic resistance to
colistin. On the other hand, Morganella morganii,
Providencia spp., Pseudomonas mallei, Burkholderia
cepacia, Chromobacterium spp., Edwardsiella spp.,
Brucella, Legionella, and Vibrio cholera are typically
resistant to colistin. Colistin is not active against Gram-
negative cocci, such as Neisseria spp., gramGram-positive
bacteria, anaerobic bacteria, eukaryotic microbes, or mam-
malian cells.14,27–31
Mechanisms of colistin resistance in
Enterobacteriaceae
Although the main mechanism of resistance to colistin is
unclear, Gram-negative bacteria employ several mechan-
isms to protect themselves against colistin toward other
polymyxins (Figure 1). According to the literature, most
colistin-resistance mechanisms are adaptive mechanisms
ithat occur after in vitro exposure.15 Resistance to colistin
occur with LPS modification via different routes. The most
common strategies for resistance to colistin are modifica-
tions of the bacterial outer membrane through alteration of
the LPS and reduction in its negative charge.32,33 The
other strategy is the overexpression of efflux-pump
systems.34 Another mechanism is overproduction of cap-
sule polysaccharide.35–37 No enzymatic mechanisms of
resistance have been reported, but strains of P. polymyxa
produce colistinase.38
Intrinsic resistance mechanisms
Resistance to polymyxins occurs naturally in P. mirabilis and
S. marcesens by modification of the LPS via cationic substitu-
tion. The mechanism of resistance in these species is linked to
expression of the arnBCADTEF operon and the eptB gene. In
this way, the 4-amino-4-deoxy-L-arabinose (L-Ara4N) and
phosphoethanolamine (pEtN) cationic groups are added to
the LPS by this operon and gene, respectively. It has been
shown that the LPS of P. mirabilis contains L-Ara4N and the
genome of this bacterium contains the eptC gene, which is
mediated to the modification of LPS with PETN.39–41 Putative
loci in P. mirabilis include the sap operon encoding a transport
protein, ATPase gene, and O-acetyltransferase gene, which
take part in biosynthesis or transfer of amino arabinose.42
Also, the existence of rppA/rppB TCS has been discovered
to play a role in activation of the arnBCADTEF operon.43,44
Similarly, this operon is responsible for intrinsic resistance to
colistin in S. marcescens, as it has been shown that arnB and
arnC mutants lead to a reduction insusceptibility to colistin
(minimum inhibitory concentration [MIC] from 2,048 to 2 µg/
mL) compared to the wild type.45
This modification of LPS and the increase inits charge give
rise to the affinity of colistin decrease for binding to LPS.
Therefore, intrinsic resistance has occurred in these
species.9,41,43
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Acquired resistance mechanisms in
Enterobacteriaceae
Acquired colistin-resistance mechanisms have been
recognized in some members of Enterobacteriaceae
family, such as E. coli, Salmonella spp., Klebsiella
spp., and Enterobacter spp., and remain unknown for
other bacterial species. Resistance mechanisms are pre-
sumed to be linked to chromosomal mutation untrans-
ferable via horizontal gene transfer.46–48 Only one
mechanism of resistance has been identified as
a transferable mechanism (plasmid-mediated mcr
gene) so far (Table 1).9,21
Many genes and operons play a role in modification
of LPS, which in turn leads to colistin resistance. These
include: genes and operons responsible for encoding
enzymes that have a direct role in LPS modification,
such as the pmrC and pmrE genes and the
pmrHFIJKLM operon;46,49 regulatory two-component
systems (TCSs), including PmrAB and PhoPQ, as well
as crrAB, which regulates the PmrAB system;50–52 the
mgrB gene, a negative regulator of TCSs, including
PmrAB and PhoPQ;53 plasmid-mediated mcr
genes;54,55 and Cpx and Rcs as regulator of upregulation
of capsule biosynthesis and activator of the efflux pump
KpnEF regulating the PhoPQ system, respectively.8
mgrB gene and regulators of PmrAB and PhoPQ
two-component systems
Some operons and regulators have a role in the modifica-
tion of LPS by PmrAB and PhoPQ TCSs. The pmrABC
operon encodes PmrA (BasR) as a regulator protein,
PmrB (BasS) as a cytoplasmic membrane-bound sensor
kinase, and PmrC as a putative membrane protein.56 The
addition of L-arabinoseamine (L-Ara4N) to the 1-phos-
phate or 4
́
-phosphate group leads to colistin resistance.46
Generally, L-Ara4N is connected to 4
́
-phosphate and
modifies it while PETN is connected to 1-phosphate.57,58
The pmrHFIJKLM operon (also named arnBCDADTEF
or pbgPE) and PmrE synthesize L-Ara4N from uridine
diphosphate glucuronic acid and fix it to lipid A.59,60 The
biosynthesis of L-Ara4N depends on the pmr (arn)
operon.61 Moreover, under environmental stimulants,
such as macrophage phagosomes, the high concentration
of iron (Fe3+) and exposure to aluminum (Al3+), as well
as acidic pH, leads to activation of PmrB.56,62 On the
other hand, low concentration of Mg2+ or Ca2+ leads to
activation of phoQ.63,64 PmrB activates PmrA by phos-
phorylation, and PmrA in turns activates regulation of the
pmrABC and pmrHFIJKLM operons and the pmrE gene.
Subsequently, these operons and genes lead to LPS mod-
ification by adding PETN and L-Ara4N to lipid A.56


















































Figure 1 Regulation and plasmid-mediated pathways of lipopolysaccharide modifications in Enterobacteriaceae.
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pmrABC and pmrFHIJKLM operons and pmrE gene.
Mutation within the pmrA and pmrB genes leading to
colistin resistance has been described in Klebsiella pneu-
moniae and Salmonella entericca (Table 1).65–69
On the other hand, the phoPQ TCS encodes PhoP as
a regulator protein and PhoQ as a sensor kinase. Under
conditions of low magnesium or calcium, acidic PH, or
cationic antimicrobial peptide, PhoPQ is activated and pro-
tects bacteria.21,63,64 Activated PhoPQ leads to modification
of lipid A via two routes: PhoQ activates PhoP by its kinase
activity via phosphorylation, which activates transcription
of the pmrFHIJKLM operon, followed by modification of
lipid A;70,71 and PhoP indirectly activates pmrA by bypass-
ing the PmrD connector protein, subsequently activates the
transcription of the pmrHFIJKLM operon and synthesizes
PETN, which transfers it to lipid A.72,73
Various of PETN-coding genes, such as eptA (pmrC),
eptB (pagC), and eptC (cptA), are able to add PETN to
different sites of LPS.74,75 Mutation of the phoP/Q genes
has been identified in K. pneumoniae and E. coli that led to
acquired colistin resistance.65,67,76–78
The mgrB gene encodes a small transmembrane protein
of 47 amino acids that exerts negative feedback on the
PhoPQ TCS.79 This protein inhibits the kinase activity of
PhoQ, which in turn represses expression of the phoQ
gene. Nevertheless, mutation/inactivation of the mgrB
gene results in upregulation of the phoPQ operon and
subsequent activation of the pmrHFIJKLM operon.
Finally, production of L-Ara4N leads to modification of
lipid A and colistin resistance.51
Various mutations or disruptions of the mgrB gene have
been reported, such as deletion, nonsense, missense, inacti-
vation, and insertional mutations. According to reports,
mgrB inactivation is the most common mechanism for
colistin resistance in K. pneumoniae and K. oxytoca.67,80–
82 In addition, it has been described that inactivation of the
mgrB gene by diverse insertion sequences at different
sites of this gene is the other mgrB mutation that often
occurs in K. pneumoniae.53,65,80 Other alterations that
have been reported in the mgrB gene include nonsense
and missense mutations, leading to premature termination
and amino-acid substitutions inmgrB, respectively.53,77
Goulian et al showed that deletion of the mgrB gene led
to upregulation of the PhoP-regulated gene in E. coli.79
CrrAB two-component system
The crrAB operon encodes two proteins: CrrA as
a regulatory protein and CrrB as a sensor kinase protein.
Wright et al described that mutation of crrB leads to colistin
resistance in K. pneumoniae.83 The mutated CrrB protein
regulates a crrAB-adjacent gene that encodes
a glycosyltransferase-like protein, which in turn leads to
modification of lipid A.83 In Cheng et al's study, six amino-
acid substitutions in the CrrB protein led to high resistance
to colistin (MICs of colistin 512–2,048 µg/mL).52 However,
mutation/inactivation of the crrB gene led to activation of
the pmrHFIJKLM operon and the pmrC and pmrE genes
through overexpression of the pmrAB operon. Furthermore,
the production and addition of L-Ara4N and PETN to lipid
A lead to acquisition of resistance to colistin.83 It was
demonstrated that CrrC afforded a connection between the
CrrAB and pmrAB systems. Mutation of the crrB gene
led to increased crrC transcription. On the other hand, it
has been suggested amino-acid substitutions of the CrrB
protein result in increased autophosphorylation of this pro-
tein, consequently leading to colistin resistance.52
Plasmid-mediated resistance to colistin
Plasmid-mediated colistin is a significant challenge and glo-
bal concern, because of easy transfer of colistin-resistance
genes to susceptible strains.54 The mcr genes are responsible
for horizontal transfer of colistin resistance. These plasmid-
mediated genes were first reported in E. coli isolated from
pigs and meat in China, November 2015.54 MCR is
a member of the PETN enzyme family, and its expression
leads to addition of PETN to lipid A. According to the
literature, isolates carrying the mcr1 gene display resistance
to colistin without other resistance mechanisms. The exis-
tence of mcr1 in isolates is enough for colistin resistance
without other resistance mechanisms, as isolates carrying this
gene displayed a four- to eightfold increase in colistin MIC.9
It is worth noting that the production of mcr1 leads to
resistance to lysozymes.84
Following initial findings, mcr1-mediating transferable
colistin resistance has been reported in several regions,
including Europe, Asia, the Americas, and Africa.85–98
There is a hypothesis that mcr1 originated in animals, parti-
cularly pigs and cattle, and subsequently spread to humans,
though the proportion of mcr1-positive isolates is low in
humans compared to animals.54,99 This transmissible gene
has been reported from diverse genera of Enterobacteriaceae,
including E. coli, Klebsiella spp., Entrobacter spp.,
Salmonella spp., Shigella spp., and Cronobacter spp., but
mostly from E. coli. Some plasmids containing the mcr1
gene carry other genes that are resistant to other antibiotics,
such as β-lactams, aminoglycosides, quinolones,
Dovepress Aghapour et al
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sulfonamides, tetracyclines, and fosfomycin.9 The mcr gene
has also been identified in Enterobacteriaceae isolates, which
carry such carbapenemase genes as blaNDM1, blaNDM5,
blaNDM9, blaOXA48, blaKPC2, and blaVIM1.
97,100,101
Recently, Xavier et al reported a novel plasmid-mediated
colistin resistance gene, known as mcr2, in E. coli.55
Thereafter, mcr3 and mcr4 genes were discovered.102,103
Finally, in July 2017, Borowiak et al reported a new gene
of the mcr family from Salmonella paratyphi B were carried
in transposons instead of plasmids.104
In addition, three mobile colistin-resistance genes (mcr6,
mcr7, and mcr8) were discovered in 2018. AbuOun et al
discovered a new variant of mcr2 from Moraxella plurani-
malium that they renamed mcr6.1.105 They suggested that
Moraxella spp. may contain a natural reservoir of mcr, and
mcr-harboring Moraxella appeared in pig populations. Yang
et al found K. pneumoniae isolates harbored a new mcr
variant, mcr7.1, recovered from chickens in China.106 They
suggested that mcr7, like mcr-3, originated from
Aeromonasspp.,102 and its structure was similar to mcr3. In
addition,mcr7 displayed 78% nucleotide identity to themcr3
gene. Eventually, a new mobile genetic element, mcr-8, was
discovered in K. pneumoniae. It was identified as the coex-
istence of mcr8 and the carbapenemase-encoding gene
blaNDM, which is a great concern.
107 It is notable that mcr8
has existed for some time and disseminated among
K. pneumoniae.107 mcr2–8 are similar to mcr1, as PETN
leads to the addition of phosphoethanolamine to lipid A,
followed by colistin resistance (Figure 1). Both mcr1 and
mcr2 genes originated fromMoraxella spp. In addition,mcr3
and mcr4 genes line up closely with PETN from Aeromonas
spp. and Shewanella frigidimarina, respectively,55,102,103,108
whereas the origin of mcr5 remains unknown.104 Although
mcr is a plasmid-mediated gene, recently Zurfluh et al iden-
tified the mcr1 gene on chromosomes of E. coli strains.
Therefore, there is a hypothesis that this gene can be inte-
grated in the genome of some isolates.109
Role of regulator RamA
The ramA locus has three genes: ramA, romA, and ramR. The
ramR gene plays a role as a repressor of the ramA and romA
genes. Some Enterobacteriaceae possess a ramA regulator,
such as K. pneumoniae, Citrobacter spp., Enterobacter spp.,
and Salmonella spp. In K. pneumoniae, this regulator mod-
ulates lipid A biosynthesis and is related to permeability
barriers. It has been shown that ramA alterations lead to
reductions in colistin susceptibility. Recently, researchers
showed that increased levels of RamA resulted in LPS
modification and increased resistance to colistin.110 RamA
applied changes tothe bacterial surface and Klebsiella
survived against colistin. Several genes are associated with
lipid A biosynthesis, including lpxA, lpxC, lpxD, lpxB, lpxK,
lpxL, lpxM, and lpxO.111 RamA binds directly to and acti-
vates the lpxC, lpxO, and lpxL2 genes and leads to alterations
within the lipid A moiety in K. pneumoniae. Therefore,
Klebsiella can survive in such antibiotic challenges as
colistin.110
Role of capsule in colistin resistance
The role of capsular polysaccharide (CPS) has been
demonstrated to be protective against cationic antimicro-
bial peptides, including colistin.35 K. pneumoniae is able
to release CPS from its surface.112 The number of capsule
layers is related to resistance level. It has been observed
that K. pneumoniae with several layers was more resistant
to colistin than isolates with few layers.8,113 However,
upregulation of a capsular biosynthesis gene led to
a reduction in the interaction of colistin with the target
site in K. pneumoniae, followed by increased colistin
resistance.35 Consequently, there are some regulators of
capsule formation, such as Cpx (conjugative pilus expres-
sion) and Rcs (regulator of capsule synthesis). Cpx and
Rcs also appear to contribute to colistin resistance by
activating the efflux pump KpnEF and regulating the
PhoPQ TCS, respectively.46 Furthermore, the ugd gene
plays a role in CPS and L-Ara4N biosynthesis in that its
phosphorylation is related to the synthesis of capsular and
colistin resistance.114,115
Role of efflux pumps
A few studies have suggested that efflux-pump systems are
involved in colistin resistance. Efflux pumps, such as the
KpnEF, AcrAB and Sap proteins, have been reported in
Enterobactericeae. By activation of these pumps, resistance
to colistin is increased.116,117 The efflux pump KpnEF is
a member of the Cpx regulon (responsible for capsule synth-
esis in K. pneumoniae) and belongs to the SMR protein
family.8 In K. pneumoniae, this pump is mediated by colistin
resistance and other antibiotics, including ceftriaxone, erythro-
mycin, and rifampicin.117 It has been observed that
mutations in KpnEF (as a member of the small MDR efflux-
pump family) lead to more susceptibility and a doubled reduc-
tion inthe MIC of colistin.117 On the other hand, AcrAB is
a part of the AcrAB–TolC complex, which plays a role in
colistin resistance. The AcrAB-mutant E. coli
displays aneightfold increase in colistin susceptibility. It has
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been remarked that expression of this pump's proteins is depen-
dent on the PhoPQ TCS.118 Finally, the SapABCDF operon
encodes Sap proteins that are constitute of five proteins.118 In
the mutant of P. mirabilis, susceptibility to colistin is increased
by mutation of the SapABCDEF operon.42 It has been shown
that the use of efflux-pump inhibitors in the test medium
carbonyl cyanide 3-chlorophenylhydrazone leads to
a reduction in MIC for colistin-resistant strains.119
Logical approaches to use of colistin
Recent studies have suggested colistin is the foremost thera-
peutic option of XDR Gram-negative bacteria in recent years,
owing to its potent bactericidal efficacy.120 Combination thera-
pies of colistin with other antibiotics are superior to colistin
monotherapy for XDR strains, due to rapid selection of resis-
tance in some strains, heteroresistance during colistin mono-
therapy, and lower clinical efficacy during colistin-based
combination.121 In addition, rates of cure, 14-day survival,
and microbiological eradication are lower in monotherapy
compared to combination therapy.121 Moreover, several com-
bination therapies have been recommended to decrease the
development of resistance. The combination of colistin with
other drugs, such as carbapenems, sulbactam, tigecycline,
aminoglycosides, and rifampicin, has been recommended to
prevent the development of colistin-resistant strains, which
may improve clinical and microbiological outcomes.121–126
The colistin–sulbactam combination was recommended
against imipenem-resistant A. baumannii, particularly in colis-
tin-resistant strains, due to its high in vitro synergistic
activity,121,127 which may be a more favorable combination.
Colistin-based combinations with tigecycline, aminoglyco-
sides, and rifampicin have shown synergistic activity against
XDR strains,122,125,128 but tigesycline is disadvantageous in
bacteremic patients, because of its low plasma
concentrations.128 In addition, colistin–carbapenem
combinations may be preferable in the treatment of
A. baumannii infections to prevent resistance selection and
to decrease the prevalence of A. baumannii.121
Conclusion
The main target for colistin is lipid A of the LPS in Gram-
negative bacteria, leading to disruption of the bacterial
membrane and resulting in cellular death. In recent dec-
ades, the increasing use of colistin in clinical settings,
mainly in veterinary clinics, has led to the emergence of
colistin resistance. Many studies have shown that the pre-
valence of colistin resistance has increased rapidly among
Enterobacteriaceae. Clinicians should be alert to the
possibility of colistin resistance among MDR bacteria
and the development of colistin resistance through muta-
tion or adaptation mechanisms. Rapidly emerging bacterial
resistance has made it harder for us to rely completelyon
the discovery of new antibiotics; therefore, we need to
have logical approaches to use older antibiotics, such as
colistin.
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